Integra LifeSciences (NASDAQ:IART) Stock Rating Upgraded by Wall Street Zen

Integra LifeSciences (NASDAQ:IART) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Other equities analysts have also recently issued reports about the company. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $11.00 to $16.00 in a report on Thursday, May 28th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Truist Financial reduced their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Finally, Wells Fargo & Company increased their target price on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Integra LifeSciences has an average rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Stock Up 1.5%

IART stock opened at $17.77 on Friday. The company has a market cap of $1.38 billion, a P/E ratio of -2.75, a P/E/G ratio of 1.21 and a beta of 1.24. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $18.05. The company’s 50-day moving average price is $13.28 and its 200 day moving average price is $12.20. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, research analysts expect that Integra LifeSciences will post 2.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently made changes to their positions in IART. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $25,000. Osaic Holdings Inc. raised its holdings in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the period. GAMMA Investing LLC raised its holdings in shares of Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 3,742 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Integra LifeSciences in the 4th quarter worth about $124,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.